Printer Friendly

SPECTRAL DIAGNOSTICS INC. RECEIVES PATENT ALLOWANCE PROVIDING EXCLUSIVE RIGHTS TO USE AND CONCEPT FOR ITS CARDIAC DIAGNOSTIC KIT

 TORONTO, Oct. 28 /PRNewswire/ -- Spectral Diagnostics Inc. (NASDAQ Small Cap: DIAGF; Canadian Dealing Network: SPTR), the developer of a systems approach to cardiac diagnostics, reported today that on Oct. 19, 1993, the first of four Cardiac Diagnostic Patent Applications has been allowed by the United States Patent and Trademark Office. The allowed claims relate to a diagnostic kit and a method of using such a diagnostic kit for an early and rapid diagnosis of the cause of chest pain. The allowed claims include a diagnostic kit in a panel format. The diagnostic kit detects the presence of at least three analytes present in a blood sample, which analytes include myoglobin, myosin light chains and at least one protein selected from the group consisting of CK-MB, Troponin I, and Troponin T.
 In making the announcement Douglas C. Ball, chairman, said, "Current standard diagnostic methods cannot reliably and rapidly distinguish the cause of chest pain -- be it a heart attack, unstable angina or simply heartburn. Treatment for heart attack and unstable angina is widely available and effective but tragically, at the time immediately preceeding the onset of chest pain, current standard diagnostic methods are neither sensitive, specific, rapid nor easy to use.
 "Today," Mr. Ball explained, "the health care system is obliged to operate with an abundance of caution by admitting chest pain patients for a two-to-four-day hospital stay for observation and rule out of heart attack. From the estimated 25 million chest pain patients annually worldwide, millions needlessly spend several days in a hospital resulting in misappropriated health care expenditures approaching $25 billion a year in the U.S. alone. Many are denied the opportunity for effective treatment.
 "This patent allowance now establishes Spectral's exclusive rights to the use and concept for its cardiac panel test," Mr. Ball added, "and we are very pleased with the outstanding commercial prospects represented by our unique and now-patent allowed concept to derive a differential diagnosis for chest pain patients by the measurement of three or more cardiac markers. This patent allowance is another very important milestone in the development of the company."
 Spectral, together with Baxter Diagnostics and Princeton Biomedica, is developing a unique systems approach to cardiac diagnostics that includes an easy-to-use, rapid and sensitive panel test requiring only three drops of blood and eight minutes reaction time.
 Spectral Diagnostics Inc., Toronto, has developed a systems approach to cardiac diagnostics that includes its proprietary Cardiac Panel. The Cardiac Panel distinguishes, for the first time, heart from non-heart ailments and unstable angina from a myocardial infarction (heart attack) -- without the use or dependence on expensive laboratory equipment. Spectral's Cardiac Panel, slightly larger than a credit card, is easy to use, requires only a few drops of a patient's blood and provides a differential diagnosis in approximately eight minutes. Patent applications have been filed in 18 countries. The Cardiac Panel, in combination with Spectral's library of cardiac proteins and antibodies, will complete the systems approach to cardiac diagnostics.
 Spectral's common shares are listed on the NASDAQ Exchange in the United States and the Canadian Dealing Network (CDN) in Canada. Spectral's trading symbols are DIAGF on the NASDAQ Exchange and SPTR on the Canadian Dealing Network.
 -0- 10/28/93
 /CONTACT: Douglas C. Ball, chairman and CEO of Spectral Diagnostics, 416-626-3233; Fred Greenberg or James McLaren of EGS Securities, 212-557-7577; or Irving L. Straus, chairman of Straus Corporate Communications, 212-768-2477/
 (DIAGF)


CO: Spectral Diagnostics Inc. ST: Ontario IN: MTC SU:

LG-TW -- NY027 -- 7764 10/28/93 09:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 28, 1993
Words:583
Previous Article:GREENFIELD INDUSTRIES, INC., ANNOUNCES THIRD QUARTER RESULTS
Next Article:SHANGHAI PETROCHEMICAL ANNOUNCES 1993 INTERIM RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters